Neurochemical, immunological and pharmacological assessments in a transgenic mouse model of the endocrine changes in depression

Aging Clinical and Experimental Research

Volumn 9, Issue 4 SUPPL., 1997, Pages 26-27

  Marchetti, B ^a,b   Morale, M C ^b   Gallo, F ^a   Brouwer, J ^c   Tirolo, C ^b   Testa, N ^b   Farinella, Z ^a   Dijkistra, C D ^c   Barden, N ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CHEMISTRY; DEPRESSION; DISEASE MODEL; DRUG EFFECT; ENDOCRINE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ANIMALS; DEPRESSION; DISEASE MODELS, ANIMAL; ENDOCRINE SYSTEM; MICE; MICE, TRANSGENIC; NEUROIMMUNOMODULATION;

EID: 0031308209     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339692     Document Type: Article

References (14)

1. Pepin M.C., Beaulieu S., Barden N.: Antidepressant regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol. Brain Res. 6: 77-83, 1989.
2. Barden N.: Molecular genetics of mood disorders. Future Health Perspectives 12: 8-10, 1991.
3. Peiffer A., Veilleux S., Barden N.: Antidepressant and other centrally acting drugs regulate glucocorticoid receptor mRNA levels in rat brain. Psychoneuroendocrinology 15: 505-515, 1991.
4. Pépin M.C., Pothier F., Barden N.: Impaired type II gluco-corticoid-receptor function in mice bearing antisense RNA transgene. Nature 355: 725-728, 1992.
5. Barden N.: In vitro effect of a type II glucocorticoid receptor (GR) antisense RNA. Ann. NY Acad. Sci. 746: 89-105, 1994.
6. Stea I., Barden N., Reul J.M.H., Holsbom F.: Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J. Psychiatr. Res. 28: 1-5, 1994.
7. Marchetti B., Peiffer A., Morale M.C., Batticane N., Gallo F., Barden N.: Transgenic animals with impaired type II glucocorticoid receptor expression: a model to study aging of the neuroendocrine immune system. Ann. NY. Acad. Sci. 719: 308-327, 1994.
8. Morale M.C., Batticane N., Gallo F., Barden N., Marchetti B.: Disruption of hypothalamic-pituitary-adrenocortical system in transgenic mice expressing type II glucocorticoid receptor antisense ribonucleic acid permanently impairs T-cell functions: effects on T-cell trafficking and T-cell responsiveness during post-natal maturation. Endocrinology 136: 3949-3960, 1995.
9. Peiffer A., Morale M.C., Barden N., Marchetti B.: Modulation of glucocorticoid receptor gene expression in the thymus by the sex steroid hormone milieu and correlation with sexual dimorphism of immune response. Endocr. J. 2: 181-192, 1994.
10. Sternberg E.M.: The role of the hypothalamic-pituitary-adrenal axis in an experimental model of arthritis. Progr. Neuroendocrinimmunol. 2: 103-108, 1989.
11. Wick G., Hu Y., Schwarz S., Kroemer G.: Immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune diseases. Endocr. Rev. 14: 539-563, 1993.
12. Sapolsky R.P., Krey L.C., McEwen B.S.: The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr. Rev. 7: 284-301, 1986.
13. Marchetti B.: The LHRH-Astroglia Network of signals as a Model to study Neuroimmune Interactions: Assessment of Messenger Systems, Transduction Mechanisms at Cellular and Molecular Levels". Neuroimmunomodulation 3: 1-27, 1996.
14. Marchetti B.: Cross-talk signals between pathways in the CNS: Role of neurotrophic and hormonal factors, adhesion molecules and intercellular signaling agents in luteinizing hormone-releasing hormone (LHRH) neuron-astroglial interactions. Frontiers in Bioscience 2: 88-125, 1997.